Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.
about
Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapiesValidity of the work productivity and activity impairment questionnaire--general health version in patients with rheumatoid arthritis.Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature.Body Region Involvement and Quality of Life in Psoriasis: Analysis of a Randomized Controlled Trial of Adalimumab.Depression and quality of life in psoriasis.Psoriasis and its treatment with adalimumab.The therapeutic potential of TNF-alpha antagonists for skin psoriasis comorbidities.Effect of Biologic Agents on Non-PASI Outcomes in Moderate-to-Severe Plaque Psoriasis: Systematic Review and Meta-Analyses.Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies.Cost effectiveness of biologic therapies for plaque psoriasis.Efficacy and safety of biologics in the treatment of moderate to severe psoriasis: a comprehensive meta-analysis of randomized controlled trials.Fatigue in psoriasis: a phenomenon to be explored.Adalimumab: A Review in Chronic Plaque Psoriasis.A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis.TNFα- and IL-17A-mediated S100A8 expression is regulated by p38 MAPK.Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study.The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients.Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis.Pruritus and quality of life in moderate-to-severe plaque psoriasis: post hoc explorative analysis from the PRISTINE study.Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption.Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial.Qualitative assessment of the content validity of the Dermatology Life Quality Index in patients with moderate to severe psoriasis.Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2.A multicenter open-label experience on the response of psoriasis to Adalimumab and effect of dose escalation in non-responders: the Aphrodite project.Reduction in psoriasis related pruritus during biologic therapy.
P2860
Q26764867-B2BD2C10-E6A5-4999-8A1B-511DF851635EQ34346259-B12338B4-1181-4F83-97E2-7A8B9A817C4AQ37303223-29D7DB4D-B4A5-4153-849D-379F73C48000Q37416210-7EF45273-E13A-4108-80F1-F284AB6DCE0CQ37566094-814D6E99-368D-403B-863D-5AED8C7EAC63Q37676220-CDD0F6C4-ED83-44C5-83FD-6BFC217C12AEQ37766229-65DD6AFF-6161-4649-B35C-875C4077D870Q38064467-BEDA5960-C13E-4765-BC11-CAF3607CAC20Q38083089-AA1B6C4A-43EA-4727-A048-2FE3C37A1668Q38108567-519C3B26-9D0A-402F-8254-3FC66373D935Q38268725-E3C04470-52E8-465F-8A1B-2848BD46926BQ38306698-BDFE4692-BF8D-4876-937E-48B68C3DF926Q38639495-67FADAE9-FEFC-451D-A73E-AFFC723B38C9Q38858335-9CD68DE8-0980-41FA-9CDA-145BE61802A2Q44044237-2A001A20-57CF-4A81-B879-B6D4FF14E4A3Q44554932-E68EA371-2FE8-49BE-B2F6-89DD539CEF59Q46356347-86CDDBE9-7CAE-4B72-A09B-8526D965EE0FQ47260366-15C1B669-CE93-4B50-9DF5-D845D3BAF303Q47644680-3F803E92-CCDD-461A-B9CB-BBA271200C9EQ47791659-63692C38-38CB-4BC0-8FC2-4677143FD668Q48063769-7BB0FCBB-3D91-4AFA-A8C7-C69B1103F6D3Q48227772-FA980A6A-1E09-47EB-A4AD-1760090AAC35Q48566723-BFF1D4C5-9C2D-40BD-9A88-F005CF6842BCQ48776801-2233F065-5E46-49D3-9354-0C13DF0B485EQ51753166-E4DDCFF4-7205-4F27-9439-4F8A63D8A274Q53548550-EC774A9D-E7F1-4616-8C92-89F0F9CC0D18
P2860
Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Impact of adalimumab treatment ...... te to severe plaque psoriasis.
@en
Impact of adalimumab treatment ...... te to severe plaque psoriasis.
@nl
type
label
Impact of adalimumab treatment ...... te to severe plaque psoriasis.
@en
Impact of adalimumab treatment ...... te to severe plaque psoriasis.
@nl
prefLabel
Impact of adalimumab treatment ...... te to severe plaque psoriasis.
@en
Impact of adalimumab treatment ...... te to severe plaque psoriasis.
@nl
P2093
P2860
P921
P1476
Impact of adalimumab treatment ...... ate to severe plaque psoriasis
@en
P2093
Alan Menter
Craig L Leonardi
Dennis A Revicki
Kenneth B Gordon
Martin Okun
Mary Kaye Willian
Miriam Kimel
Richard G Langley
P2860
P304
P356
10.1080/09546630701646172
P577
2007-01-01T00:00:00Z